Holen Sie sich die Stockscreener-App
109.35
0.88%
0.95
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis
Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar
Chemical Biology in Biomedical Research - Novartis
Radioligand therapy: delivering now, building for the future - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Inclusivity - Novartis
Collaborations - Novartis
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial - GlobeNewswire Inc.
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart
21 Best Healthcare Companies to Invest In - Morningstar
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise
Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
NVS: 3 European Stocks to Watch as the EU Economy Strengthens - StockNews.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar
Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart
Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart
North America Immune Health Supplements Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News
Novartis lower as BofA downgrades on risks to valuation - MSN
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.
Morgan Stanley cuts Novartis rating amid limited innovation - Baystreet.ca
Spain Congestive Heart Failure Drugs Market Size & Outlook, 2030 - Grand View Research
Market Insight: Novartis AG ADR (NVS)’s Notable Drop, Closing at 118.50 - The Dwinnex
Canada Cell And Gene Therapy CDMO Market Size & Outlook, 2030 - Grand View Research
The United States Erythropoietin Drugs Market Size & Outlook, 2030 - Grand View Research
China Biotechnology Market Size & Outlook, 2023-2030 - Grand View Research
Kuwait Gout Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research
0.29%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):